Research groups
Colleges
DPhil projects available
AKR1C1 as a therapeutic target in non-alcholoic fatty liver diease and hepatocellular carcinoma
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Key publications
-
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.
Journal article
Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113
-
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Journal article
Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408
-
5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.
Journal article
Nasiri M. et al, (2015), Endocrinology, 156, 2863 - 2871
Recent publications
-
The ALIOS diet in male and female rodents recapitulates the clinical and transcriptomic features of NAFLD and NASH.
Journal article
Harris SE. et al, (2020), Am J Physiol Gastrointest Liver Physiol
-
The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1.
Journal article
Barnard L. et al, (2020), J Steroid Biochem Mol Biol, 202
-
Fighting liver fat.
Journal article
Koeckerling D. et al, (2020), Endocr Connect
-
Guidance for the prevention and emergency management of adult patients with adrenal insufficiency.
Journal article
Simpson H. et al, (2020), Clinical medicine (London, England), 20, 371 - 378
-
Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids.
Journal article
Othonos N. et al, (2020), J Clin Endocrinol Metab